Kirsten L Viola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7115167/publications.pdf

Version: 2024-02-01

361413 552781 7,639 27 20 26 citations h-index g-index papers 33 33 33 7904 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	${\sf A}{\sf \hat{I}}^2$ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease. Journal of Neuroscience, 2007, 27, 796-807.	3.6	1,090
2	Alzheimer's disease-affected brain: Presence of oligomeric $A\hat{l}^2$ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10417-10422.	7.1	995
3	Synaptic Targeting by Alzheimer's-Related Amyloid \hat{l}^2 Oligomers. Journal of Neuroscience, 2004, 24, 10191-10200.	3.6	905
4	${\sf A}{\sf \hat{I}}^2$ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine. Journal of Biological Chemistry, 2007, 282, 11590-11601.	3.4	769
5	Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of $\hat{Al^2}$ oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1971-1976.	7.1	592
6	The Amyloid- \hat{l}^2 Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease, 2018, 64, S567-S610.	2.6	572
7	Soluble oligomers of \hat{I}^2 amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Research, 2002, 924, 133-140.	2.2	515
8	Self-Assembly of Al̂² ₁ ₋ ₄₂ into Globular Neurotoxins. Biochemistry, 2003, 42, 12749-12760.	2.5	511
9	Amyloid \hat{l}^2 oligomers in Alzheimerâ \in ^M s disease pathogenesis, treatment, and diagnosis. Acta Neuropathologica, 2015, 129, 183-206.	7.7	490
10	Vaccination with soluble Al̂² oligomers generates toxicityâ€neutralizing antibodies. Journal of Neurochemistry, 2001, 79, 595-605.	3.9	309
11	Monoclonal antibodies that target pathological assemblies of $\hat{A^2}$. Journal of Neurochemistry, 2007, 100, 23-35.	3.9	308
12	Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nature Nanotechnology, 2015, 10, 91-98.	31.5	155
13	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound $\hat{Al^2}$ oligomers. Molecular Biology of the Cell, 2017, 28, 2623-2636.	2.1	88
14	Brain Transit and Ameliorative Effects of Intranasally Delivered Anti-Amyloid-Î ² Oligomer Antibody in 5XFAD Mice. Journal of Alzheimer's Disease, 2013, 35, 777-788.	2.6	56
15	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1140.	2.4	46
16	Synapse-Binding Subpopulations of ${\hat {A}}^2$ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies. ACS Chemical Neuroscience, 2012, 3, 972-981.	3.5	45
17	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer's disease. Nature Communications, 2022, 13, 159.	12.8	42
18	Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid & Epitopes of Epitopes of Amyloid & Epitopes of Epitopes	1.4	29

#	Article	IF	CITATION
19	A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloidâ€Î² oligomers. Journal of Neurochemistry, 2017, 142, 934-947.	3.9	27
20	Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer's patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability. Neuropathology and Applied Neurobiology, 2021, 47, 488-505.	3.2	25
21	Elucidating Molecular Mass and Shape of a Neurotoxic A \hat{l}^2 Oligomer. ACS Chemical Neuroscience, 2014, 5, 1238-1245.	3.5	24
22	Soluble state high resolution atomic force microscopy study of Alzheimer's β-amyloid oligomers. Applied Physics Letters, 2009, 95, 183701.	3. 3	17
23	The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 768646.	2.8	10
24	Insights into the mechanism of Alzheimerâ \in TM s β-amyloid aggregation as a function of concentration by using atomic force microscopy. Applied Physics Letters, 2012, 100, .	3.3	7
25	An Essential Role for Alzheimer's-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis. International Journal of Molecular Sciences, 2022, 23, 2208.	4.1	5
26	Aβ oligomer induced cognitive impairment and evaluation of ACU193â€MNSâ€based MRI in rabbit. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12087.	3.7	4
27	P4-177: An ultrasensitive immunoassay detects soluble AÎ 2 oligomers in tg mice prior to memory loss. , 2015, 11, P847-P847.		0